KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $4.6 million.

  • Aurinia Pharmaceuticals' Current Deferred Revenue rose 692.38% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 692.38%. This contributed to the annual value of $11.0 million for FY2024, which is 12858.92% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Current Deferred Revenue stood at $4.6 million, which was up 692.38% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Current Deferred Revenue registered a high of $11.0 million during Q4 2024, and its lowest value of $190000.0 during Q4 2021.
  • For the 5-year period, Aurinia Pharmaceuticals' Current Deferred Revenue averaged around $4.5 million, with its median value being $4.6 million (2025).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 155684.21% in 2022, then plummeted by 767.91% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $190000.0 in 2021, then soared by 1556.84% to $3.1 million in 2022, then soared by 52.89% to $4.8 million in 2023, then skyrocketed by 128.59% to $11.0 million in 2024, then crashed by 58.17% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $5.5 million for Q2 2025, and $4.6 million during Q1 2025.